Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Kashiv BioSciences has a diverse pipeline including biosimilars of leading global brands in oncology and immunology. The company has achieved successful Phase I results for an abatacept biosimilar candidate ("KSHB002"), obtained Health Canada approval for pegfilgrastim injection, and submitted a marketing application to the UK MHRA for ADL‑018—a proposed omalizumab biosimilar. The company’s platforms enable differentiated drug delivery approaches across small molecules and biologics
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on KASWAY BIOTECH.